Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Hui-Ming Chang

CredentialsActive State Medical License, California
Active State Medical License, Massachusetts
Active State Medical License, Texas
American Board of Anesthesiology
TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentPharmacology & Toxicology, College of Medicine
Address325 S. Elm St.
Mail Slot # 611
Little Rock AR 72205
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionUniversity of Arkansas for Medical Sciences
    DepartmentInternal Medicine, College of Medicine
    DivisionCardiovascular Medicine


    Collapse Overview 
    Collapse overview
    Dr. Hui-Ming Chang is a cross-discipline physician scientist with academic leadership experience in research, administration, education, and clinical medicine. She received her medical degree from National Taiwan University, master of public health in Epidemiology and master of science in Physiology from Harvard Chan School of Public Health. Her post-graduate trainings include internship at George Washington University Medical Center, residency at Boston University Medical Center, and clinical and research fellowship at Harvard Medical School, Boston Children’s Hospital. Dr. Chang came to UAMS from University of Missouri School of Medicine where she was co-director of the Center for Precision Medicine. Prior to U. of Missouri, she was faculty at Harvard Medical School, Massachusetts General Hospital, U. of Texas MD Anderson Cancer Center, and U. of Texas Health Science Center at Houston. Her prior academic positions include vice president for international programs and special advisor to the president at the U. of Texas Health Science Center at Houston, director of senior clinical performance examination at U. of Texas Houston Medical School, and director of education, Department of Palliative Care and Rehabilitation at U. of Texas MD Anderson Cancer Center.

    Her services on national and institutional committees include Board of Directors of the American Academy of Pain Medicine, Task Force for clinical practice guidelines-cancer pain management of the American Society of Anesthesiologists, Executive Council of the U. of Texas at Houston, Search Committee for President of the U. of Texas at Houston, and scientific advisory committee of the university clinical research center at the U. of Texas at Houston and M.D. Anderson Cancer Center. She was the recipient of Fleming and Davenport award and medical honoree of American Heart Association Houston Heart Ball. She was nominated for Councilor position, alumni association of Harvard Chan School of Public Health in 2020.
    Her contributions to medical sciences include opioid effects on evoked substance P release from primary sensory neurons, co-authoring the discovery of SUMO/Sentrin, and the cloning of Class H defect in Glycosylphosphatidylinositol Anchor. Recently she devoted majority of her time on onco-cardiology (cardio-oncology). With her cross-discipline expertise in epidemiology, evidence-based medicine, and basic research, she translated bench laboratory data to bedside clinical trials for prevention of doxorubicin-induced cardiotoxicity. This investigator initiated clinical trials received 3.48 million NIH RO1 award, HL 151993, 6/2020-5/2025.


    Collapse Biography 
    Collapse Leadership and Administrative Roles
    Co-Director 2016-2020
    Center for Precision Medicine
    University of Missouri
    Columbia, MO

    Special Advisor to the President 2001-2008
    University of Texas Health Science Center at Houston
    Houston, TX

    Vice President 2006-2008
    International Programs
    University of Texas Health Science Center at Houston Houston, TX

    Associate Vice President of International Programs 2001-2006
    University of Texas Health Science Center at Houston
    Houston, TX

    Director of Education 2000-2003
    Department of Palliative Care and Rehabilitation
    University of Texas, M.D. Anderson Cancer Center
    Houston, TX

    Course Director 1997-2003
    Senior Clinical Rotation
    (Palliative Care, Pain Management and Symptom Control)
    University of Texas Medical School at Houston
    University of Texas, M.D. Anderson Cancer Center
    Houston, TX

    Director 1996-2001
    Senior Clinical Performance Examination
    (Standardized Patient OSCE Examination)
    University of Texas Medical School at Houston
    Houston, TX

    Collapse education and training
    Harvard Medical School, Boston Children's Hospital, Boston MA02/1988Clinical Fellow
    Harvard Medical School, Boston Children's Hospital, Boston MA02/1988Research Fellow
    Boston University Medical Center, Boston MA06/1986Resident, Anesthesiology
    George Washington University Medical Center, Washington DC6/1984Intern
    Harvard Chan School of Public Health, Boston MAMPH6/1982Epidemiology
    Harvard Chan School of Public Health, Boston MAMS6/1983Physiology
    National Taiwan University, Taipei TaiwanMD6/19807 year medical school
    Collapse awards and honors
    2020Nominated, Councilor position, Alumni Association, Harvard Chan School of Public Health
    2011Medical Honoree, American Heart Association, Houston Heart Ball
    2001 - 2006Fleming and Davenport Awards, University of Texas MD Anderson Cancer Center
    1981Scholar, Harvard Alumni Association, Taipei

    Collapse Research 
    Collapse research activities and funding
    R01HL151993     (CHANG, HUI-MING)Jun 15, 2020 - May 31, 2025
    NIH
    Prevention of Heart Failure induced by Doxorubicin with Early Administration of Dexrazoxane
    Role: Principal Investigator

    R01HL126916     (YEH, EDWARD T.H.)Apr 1, 2015 - Aug 31, 2021
    NIH
    Doxorubicin-induced Cardiotoxicity: the Role of Topoisomerase 2b
    Role: Co-Investigator

    R01CA080089     (YEH, EDWARD T.H.)Feb 1, 2000 - Jan 31, 2006
    NIH
    PATHOBIOCHEMISTRY OF ACUTE PROMYELOCYTIC LEUKEMIA
    Role: Co-Investigator

    R21GM057502     (YEH, EDWARD T.H.)Sep 1, 1999 - Aug 31, 2001
    NIH
    STUDIES OF THE SENTRIN FAMILY OF UBIQUITIN-LIKE PROTEINS
    Role: Co-Investigator

    R01HL045851     (YEH, EDWARD T.H.)Feb 1, 1991 - Jul 31, 1999
    NIH
    PATHOBIOLOGY OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
    Role: Co-Investigator

    Collapse Outreach 

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Sheng ZF, Zhang H, Zheng P, Chen S, Gu Z, Zhou JJ, Phaup JG, Chang HM, Yeh ETH, Pan HL, Li DP. Impaired Kv7 channel activity in the central amygdala contributes to elevated sympathetic outflow in hypertension. Cardiovasc Res. 2021 Jan 29. PMID: 33512443.
      View in: PubMed
    2. Chang HM, Yeh ETH. SUMO: From Bench to Bedside. Physiol Rev. 2020 10 01; 100(4):1599-1619. PMID: 32666886.
      View in: PubMed
    3. Li J, Chang HM, Banchs J, Araujo DM, Hassan SA, Wagar EA, Yeh ETH, Meng QH. Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin. Cardiooncology. 2020; 6:1. PMID: 32154027.
      View in: PubMed
    4. Yeh ETH, Ewer MS, Moslehi J, Dlugosz-Danecka M, Banchs J, Chang HM, Minotti G. Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology. Semin Oncol. 2019 12; 46(6):397-402. PMID: 31753424.
      View in: PubMed
    5. Yang FM, Zuo Y, Zhou W, Xia C, Hahm B, Sullivan M, Cheng J, Chang HM, Yeh ET. sNASP inhibits TLR signaling to regulate immune response in sepsis. J Clin Invest. 2018 06 01; 128(6):2459-2472. PMID: 29733298.
      View in: PubMed
    6. Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. J Am Coll Cardiol. 2017 Nov 14; 70(20):2552-2565. PMID: 29145955.
      View in: PubMed
    7. Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. J Am Coll Cardiol. 2017 Nov 14; 70(20):2536-2551. PMID: 29145954.
      View in: PubMed
    8. Yeh ETH, Chang HM. Cancer and Clot: Between a Rock and a Hard Place. J Am Coll Cardiol. 2017 08 22; 70(8):939-941. PMID: 28818203.
      View in: PubMed
    9. Chang HM, Yeh ETH. Potential of Oncocardiology-Reply. JAMA Cardiol. 2017 07 01; 2(7):818. PMID: 28273313.
      View in: PubMed
    10. Yeh ET, Chang HM. Oncocardiology-Past, Present, and Future: A Review. JAMA Cardiol. 2016 Dec 01; 1(9):1066-1072. PMID: 27541948.
      View in: PubMed
    11. Chang HM. Pain and its management in patients with cancer. Cancer Invest. 2004; 22(5):799-809. PMID: 15581060.
      View in: PubMed
    12. Chang HM. Educating medical students in pain medicine and palliative care. Pain Med. 2002 Sep; 3(3):194-5. PMID: 15099251.
      View in: PubMed
    13. Chang HM. Cancer pain management. Med Clin North Am. 1999 May; 83(3):711-36, vii. PMID: 10386122.
      View in: PubMed
    14. Okura T, Gong L, Kamitani T, Wada T, Okura I, Wei CF, Chang HM, Yeh ET. Protection against Fas/APO-1- and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J Immunol. 1996 Nov 15; 157(10):4277-81. PMID: 8906799.
      View in: PubMed
    15. Ware RE, Howard TA, Kamitani T, Chang H-M, Yeh ETH, Seldin MF. Chromosomal assignment of genes involved in glycosylphosphatidylinositol anchor biosynthesis: implications for the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood. 1994 06 15; 83(12):3753-7. PMID: 8204896.
      View in: PubMed
    16. Kamitani T, Chang HM, Rollins C, Waneck GL, Yeh ET. Correction of the class H defect in glycosylphosphatidylinositol anchor biosynthesis in Ltk- cells by a human cDNA clone. J Biol Chem. 1993 Oct 05; 268(28):20733-6. PMID: 8407896.
      View in: PubMed
    17. Yeh ET, Chang HM. Pathophysiology and principles of pain management in rheumatic diseases. Curr Opin Rheumatol. 1992 Jun; 4(3):332-6. PMID: 1599812.
      View in: PubMed
    18. Thomas LJ, Urakaze M, DeGasperi R, Kamitani T, Sugiyama E, Chang HM, Warren CD, Yeh ET. Differential expression of glycosylphosphatidylinositol-anchored proteins in a murine T cell hybridoma mutant producing limiting amounts of the glycolipid core. Implications for paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1992 Apr; 89(4):1172-7. PMID: 1532587.
      View in: PubMed
    19. DeGasperi R, Thomas LJ, Sugiyama E, Chang HM, Beck PJ, Orlean P, Albright C, Waneck G, Sambrook JF, Warren CD, et al. Correction of a defect in mammalian GPI anchor biosynthesis by a transfected yeast gene. Science. 1990 Nov 16; 250(4983):988-91. PMID: 1978413.
      View in: PubMed
    20. Chang HM, Berde CB, Holz GG, Steward GF, Kream RM. Sufentanil, morphine, met-enkephalin, and kappa-agonist (U-50,488H) inhibit substance P release from primary sensory neurons: a model for presynaptic spinal opioid actions. Anesthesiology. 1989 Apr; 70(4):672-7. PMID: 2467589.
      View in: PubMed
    Chang's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description